NEW YORK – Transplant diagnostics company CareDx has released a new version of its signature organ transplant diagnostic AlloSure, which can now detect if patients are showing signs of borderline, subclinical T-cell mediated rejection (TCMR).
AlloSure 3.0, the latest iteration of the company's donor-derived cell-free DNA (dd-cfDNA) test, is specifically meant to enable doctors to detect the earliest and most "ambiguous" signs of rejection that are often undetectable through other means," according to CareDx Chief Commercial Officer Sasha King.